






All Oral Pipeline

AREA OF THERAPY	PRECLINICAL	PHASE I	PHASE II	PHASE III	COMMERCIAL RIGHTS
HEMATOLOGIC MALIGNANCIES					
Multiple Myeloma Relapsed/refractory BOSTON		SELINEXOR + VELCADE ¹			 Karyopharm [®] Therapeutics
Penta-refractory STORM		SELINEXOR ²			
Relapsed/refractory and front-line STOMP		SELINEXOR + BACKBONE THERAPIES ³			
Diffuse Large B-cell Lymphoma SADAL		SELINEXOR			 ONO Japan*
SOLID TUMOR MALIGNANCIES					
Liposarcoma SEAL		SELINEXOR			 ANTENGENE China**
Endometrial Cancer SIENDO ⁴		SELINEXOR			
Glioblastoma KING		SELINEXOR			
ADDITIONAL ONCOLOGY PROGRAMS					
MDS, CRC, PrC		ELTANEXOR			 ANTENGENE China***
Solid Tumors & Lymphoma		KPT-9274			
OTHER INDICATIONS					
Lymphoma in Companion Animals		VERDINEXOR			 ANIVIVE LIFESCIENCES ****

Granted Priority Review by FDA with PDUFA Date of April 6, 2019

Granted Fast Track designation

Oral SINE compound and XPO1 inhibitor **KPT-350** acquired by **Biogen** for treatment of certain neurological and neurodegenerative conditions, including ALS, in Jan 2018

¹ Oral selinexor, Velcade[®] (bortezomib) and dexamethasone vs. Velcade and dexamethasone
² Oral selinexor + dexamethasone
³ Oral selinexor and dexamethasone + Revlimid[®] (lenalidomide), Pomalyst[®] (pomalidomide), Velcade, Kyprolis[®] (carfilzomib) or Darzalex[®] (daratumumab)
⁴ Investigator-sponsored randomized Phase III trial

*Territories: Japan, S. Korea, Taiwan, Hong Kong, and ASEAN countries.
 ** Antengene licensed rights to selinexor and eltanexor in China and Macau.
 *** Antengene licensed rights to KPT-9274 and verdinexor in mainland China, Macau, Taiwan, Hong Kong, South Korea, and the ASEAN countries.
 **** Anivive holds exclusive worldwide rights to research, develop and commercialize verdinexor only for the treatment of cancer in companion animals